

pAdenoX-PRLS (Linear)

Catalog No(s).

Amount

10 µl pAdenoX-PRLS (Linear) Vector (200 ng/µl)

Lot Number Specified on product label.

632260 (Not sold separately). Sold as part of 632266

pAdenoX-PRLS (Linear) Vector Information



Figure 1. pAdenoX-PRLS (Linear) vector map.

End of Packaging Signal	Sequence to be added to 5' end of forward primer		
CTCATAGCGC GTAATCTCTA	GCATCGTAAC TATAACGGTC	In-Fusion	GGAGAAAGAG GTAATGAA
GAGTATCGCG CATTAGAGAT	CGTAGCATTG ATATTGCCAG	Cloning Site	CCTCTTTCTC CATTACTT
			Sequence to be added to

5' end of reverse primer

AT GGCATCGACT CGAAGATCTG TA CCGTAGCTGA GCTTCTAGAC

Screening Primer (reverse)

Figure 2. pAdenoX-PRLS (Linear) In-Fusion cloning site.

Location of Features

- Screening Primer (reverse) [complementary]: 19-38
- ITR (inverted terminal repeat): 29251-29310 .

U.S. Technical Support: tech@clontech.com

United States/Canada	Asia Pacific	Europe	Japan	
800.662.2566	+1.650.919.7300	+33.(0)1.3904.6880	+81.(0)77.543.6116	
Late update: July 12, 2011				

Clontech Laboratories, Inc. A Takara Bio Company 1290 Terra Bella Avenue, Mountain View, CA 94043, USA

Vector Map

pAdenoX-PRLS (Linear)

- Amp^r (ampicillin resistance gene; β -lactamase): 30211–31071
- pUC origin of replication: 31716–31889
- ITR (inverted terminal repeat): 32300–32359
- Screening Primer (forward): 32403–32427
- Ψ (packaging signal): 32492–32640

NOTICE TO PURCHASER:

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, in vitro diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without prior written approval of Clontech Laboratories, Inc.

Your use of this product is also subject to compliance with the licensing requirements listed below and described on the product's web page at http://www.clontech.com. It is your responsibility to review, understand and adhere to any restrictions imposed by these statements.